Netherlands Study: Continuous Glucose Monitors Outperform Education Programs for Dangerous Lows in Type 1 Diabetes

A study from the Netherlands found that immediately starting continuous glucose monitoring (CGM) is significantly more effective than hypoglycemia-focused psychoeducation for Type 1 diabetes patients who experience dangerous low blood sugar episodes — even after those patients had already completed structured diabetes education.

What Makes This International Research Valuable for US Patients

The Netherlands has a robust, well-funded diabetes care system with high rates of structured patient education — making their population an excellent comparison point for American patients who have "already done everything right" but still struggle with severe lows. This trial specifically enrolled people who had already completed formal insulin adjustment education, closely mirroring the experience of many engaged, educated US diabetes patients who continue to face hypoglycemia challenges despite their best efforts.

What the Study Examined

Researchers at Amsterdam UMC's Diabetes Center conducted a randomized controlled trial with 52 Type 1 diabetes patients (average age 53, 56% female) who experienced problematic hypoglycemia and impaired awareness of hypoglycemia (IAH) — a dangerous condition where patients lose the ability to feel warning signs of low blood sugar. IAH affects an estimated 20–25% of people with long-standing Type 1 diabetes in the US.

Participants were split into two groups:

• Stepped-Care Group: Attended the HypoAware psychoeducation program first. CGM was only added if severe hypoglycemic events (SHEs) or IAH persisted after 6 months.
• Immediate CGM Group: Started CGM right away without the intermediate education step.

Key Findings — Converted to US Standards

At the 6-month mark, the immediate CGM group showed significantly better results across every major measure:

• Severe hypoglycemic events dropped 39% more in the CGM group compared to the psychoeducation group (p<0.05)
• HbA1c improved more in the CGM group (down 0.47 percentage points, p<0.05) — meaningful progress toward the American Diabetes Association (ADA) target of below 7.0% for most adults
• Time below range improved: The CGM group spent 2.4 percentage points less time under 54 mg/dL (3.0 mmol/L) — the threshold the ADA defines as clinically significant hypoglycemia requiring urgent action
• IAH was restored in 31% of patients in both groups, suggesting CGM did not hinder the recovery of hypoglycemia awareness

Notably, by the end of the study, 93% of the stepped-care group had ultimately started CGM anyway — suggesting the psychoeducation-first approach mainly delayed access to the more effective tool.

Why This Matters for US Patients

Many US insurance plans and clinical protocols follow a "stepped-care" model — requiring patients to try education programs or less intensive interventions before approving CGM devices. This Dutch trial directly challenges that approach for patients with IAH and recurring severe lows. The ADA's 2024 Standards of Care already recommend CGM for most people with Type 1 diabetes, but access barriers remain common. This study adds strong evidence that delaying CGM in favor of psychoeducation for high-risk patients may increase their danger window unnecessarily. If you or someone you care for has experienced severe hypoglycemia despite completing diabetes education, this research supports advocating directly for immediate CGM access with your care team or insurer.

Study Citation

Serné, van den Berg, & Racca. "Improved Effectiveness of Immediate Continuous Glucose Monitoring in Hypoglycemia-Prone People with Type 1 Diabetes Compared with Hypoglycemia-Focused Psychoeducation Following a Previous Structured Education: A Randomized Controlled Trial." Diabetes Technology & Therapeutics, 2023. PMID: 36326825. DOI: 10.1089/dia.2022.0232